Phase 3 clinical trial: Second-generation COVID vaccine generates high levels of neutralizing antibodies
by University of Washington School of MedicineVaccine GPB510 is a tiny ball of protein studded with 60 copies of the SARS-CoV-2 Spike protein receptor-binding domain (red). Credit: Ian Haydon / U
Updated on: April 02,2024
16
Phase 3 clinical trial: Second-generation COVID vaccine generates high levels of neutralizing antibodies
by University of Washington School of MedicineVaccine GPB510 is a tiny ball of protein studded with 60 copies of the SARS-CoV-2 Spike protein receptor-binding domain (red). Credit: Ian Haydon / U
Updated on:April 02,2024
16
